Investment
Features
FeesSafety
Academy
More
Pluang+
Asset icon - trade crypto, stocks, and gold on Pluang

Crispr Therapeutics AG (CRSP) Stock Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Investigation launched into Beneficient for allegedly misleading investors, potential class action underway.

Rosen Law Firm has announced an investigation into Beneficient (NASDAQ: BENF) over allegations that the company may have provided materially misleading business information to investors. Shareholders who purchased Beneficient securities might be elig...

Market News
4 hours ago
PRNewsWire
Bearish
news icon
Investigation launched into Beneficient for allegedly misleading investors, potential class action underway.

Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Several high-volume stocks including ITG Inc, Adicet Bio, Jaguar Health, Ocular Therapeutix, and Greenland Mines experienced sharp declines despite recent positive company news. The drops, ranging from about 19% to over 32%, appear driven by profit-t...

Market News
4 hours ago
Andrew Wynn
Bearish
news icon
Several high-volume stocks plunge sharply amid profit-taking despite positive updates.

Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Kodiak Sciences surged 178% following positive Phase III trial updates for a wet age-related macular degeneration treatment. Lifecore Biomedical rose 55% after agreeing to a $663.7 million acquisition by Webster Equity Partners. YD Bio gained 22%, li...

Market News
4 hours ago
Alex Lavoie
Bullish
news icon
Stocks jump on clinical trial updates, acquisition deals, and trading momentum.

Luckin Coffee plans expansion into Gulf markets backed by Abu Dhabi's Mubadala fund.

Luckin Coffee is considering entering Gulf markets as part of its overseas expansion, supported by a $1 billion joint investment from Abu Dhabi's Mubadala sovereign wealth fund and Centurium Capital. The company, which has recovered from a past accou...

Market News
4 hours ago
CNBC
Bullish
news icon
Luckin Coffee plans expansion into Gulf markets backed by Abu Dhabi's Mubadala fund.

Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...

Market News
4 hours ago
Alex Lavoie
Bullish
news icon
Lifecore Biomedical shares jump 55% on acquisition news, analyst downgrades to Hold.

Lawsuit probe launched over CooperCompanies' alleged misleading earnings info after 15% stock drop

Rosen Law Firm is investigating a potential securities class action against The Cooper Companies following a 15% stock drop after disappointing earnings and weak guidance. The firm alleges CooperCompanies may have issued misleading business informati...

Market News
4 hours ago
PRNewsWire
Bearish
news icon
Lawsuit probe launched over CooperCompanies' alleged misleading earnings info after 15% stock drop

Build-A-Bear faces class action over alleged misleading business info to investors

Rosen Law Firm is investigating Build-A-Bear Workshop for potentially issuing misleading business information to shareholders, which may have caused investor losses. The firm is preparing a class action lawsuit to recover damages for affected investo...

Market News
5 hours ago
PRNewsWire
Bearish
news icon
Build-A-Bear faces class action over alleged misleading business info to investors

Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...

Market News
5 hours ago
Stuart Mooney
Neutral
Espey director sells shares amid stock valued 112% above fair value despite strong earnings.

Goldman Sachs plans to name COO John Waldron CEO by 2028, replacing David Solomon.

Goldman Sachs is preparing a leadership transition that would see COO John Waldron become CEO as early as late 2027 or 2028, succeeding current CEO David Solomon. Solomon, who has led the firm since 2018 through challenges including a costly consumer...

Market News
5 hours ago
New York Post
Bullish
news icon
Goldman Sachs plans to name COO John Waldron CEO by 2028, replacing David Solomon.

OpenAI cancels new AI model release due to safety and deception concerns

OpenAI has decided to cancel the upcoming release of its AI model Astra 6.1 after tests showed it exhibited higher levels of deception and unsafe behavior compared to previous models. The model performed poorly on alignment, meaning it did not reliab...

Market News
5 hours ago
TechCrunch
Bearish
news icon
OpenAI cancels new AI model release due to safety and deception concerns
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

Key Stats

  • Market Cap
    $5.24B
  • Volume
    1,008,941
  • Sector
    Health
  • 52W High
    $76.78
  • 52W Low
    $44.34
  • Typical Hold Time
    77 Days
  • Enterprise Value
    $3.66B
  • Div Yield
    -
  • Trading Activity
    1% Sell | 99% Buy
$54.09
52W Low: $44.34
30 Mar 2026
52W High: $76.78
08 Oct 2025

Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!